Skip to main content
ConductScienceScienceDex
Powered by ShareScore

Find research datasets worth reusing

Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.

6,348

datasets available to search

ShareScore release 0.9.0

Reset

Dataset results

6,348 results for “hepatitis”

Learn how ShareScore rates datasets ↗
dryad36/100

Assessment of hepatitis B viral lymphotrophism using deep curation

Open the record for dataset details and reuse information.

publicJun 2022View details →
dryad36/100

Data from: Steatotic liver disease induced by TCPOBOP-activated hepatic constitutive androstane receptor: Primary and secondary gene responses with links to disease progression

Open the record for dataset details and reuse information.

publicMay 2024View details →
dryad36/100

Data from: Gut microbiome critically impacts PCB-induced changes in metabolic fingerprints and the hepatic transcriptome in mice

Open the record for dataset details and reuse information.

publicAug 2020View details →
dryad36/100

Ultra-short response-guided Hepatitis C treatment with sofosbuvir and daclatasvir: the SEARCH study HCV sequence data

Open the record for dataset details and reuse information.

publicAug 2022View details →
dryad36/100

3-(4-Hydroxy-3-methoxyphenyl) propionic acid contributes to improved hepatic lipid metabolism via GPR41

Open the record for dataset details and reuse information.

publicNov 2023View details →
dryad32/100

Untargeted LC–MS metabolomics reveals an adverse effect of high-fat diet on hepatic metabolism of Oreochromis niloticus

<p>Hepatic steatosis commonly occurs in intensively farmed tilapia. This disease is harmful to fish growth and health, but knowledge of the metabolic changes in tilapia with fatty liver is limited. In the present study, we compared genetically improved farmed tilapia (GIFT, <em>Oreochromis niloticus</em>) fed a high-fat diet (HFD) with those fed a normal-fat diet (NFD) for 8 weeks using LC-MS-based hepatic metabolomic assays and traditional nutritional assessments. Juvenile GIFT fed a HFD displayed higher fat disposition in the liver than did those fed a NFD. The metabolomic analyses revealed 61 differentially accumulated metabolites between the groups, and these metabolites were involved in 37 signaling pathways. Our results illustrate the development of metabolic disorders related to various hepatic biological processes, including protein metabolism, lipid metabolism, carbohydrate metabolism, and nucleotide metabolism in HFD-fed GIFT. These physiological changes may be related to the lower growth rate of GIFT. Overall, our study reveals the metabolic disorders in GIFT fed HFD, and enhance our knowledge of the mechanism of fatty liver formation in GIFT.</p>

opencc-zeroJun 2020View details →
dryad32/100

Data from: Early detection of chronic hepatitis B and risk factor assessment in Turkish migrants, Middle Limburg, Belgium.

Background Turkey is an intermediate hepatitis B virus (HBV) endemic country. However, prevalence among Turkish migrants in Belgium is unknown, especially in those born in Belgium with a foreign-born parent, i.e. second-generation migrants (SGM). Aims To evaluate the prevalence of HBV infection and associated risk factors in Turkish first-generation migrants (FGM), i.e. foreign-born, and SGM. Methods Between September 2017 and May 2019, free outreach testing for hepatitis B surface antigen (HBsAg), hepatitis B core antibodies (anti-HBc), and antibodies against HBsAg was offered to Turkish migrants in Middle-Limburg, Belgium. Face-to-face questionnaire assessed HBV risk factors. HBsAg positive patients were referred and followed up. Turkish SGM were stratified into birth cohort born before and after 1987, since those born after 1987 should be covered by the universal infant vaccination program. Results A total of 1,081/1,113 (97.1%) Turkish did go for HBV testing. Twenty-six (2.4%) were HBsAg positive; 11/26 were unaware of their status and 10/11 were successfully referred. HBsAg prevalence was 3.0% in FGM and 1.5% in SGM, p = .070. Only one out of seven HBsAg positive SGM was born after 1987.  In the multiple generalized estimating equations model, the most important risk factors for anti-HBc positivity were male gender ( p = .021), older age ( p &lt; .001), FGM ( p &lt; .001), low educational level of the mother ( p = .003), HBV infected mother ( p = .008), HBV infected siblings ( p = .002), HBV infected other family member ( p = .004), gynaecological examination in Turkey or unsafe male circumcision ( p = .032) and dental treatment in Turkey ( p = .049). Conclusion Outreach testing was well-accepted and referral to specialist care was generally successful. National HBV screening should be implemented in the Turkish FGM population and might be considered in SGM not covered by primary prevention strategies.

opencc-zeroDec 2019View details →
dryad32/100

Data from: Telbivudine on IgG-associated Hypergammaglobulinemia and TGF-β1 Hyperactivity in Hepatitis B Virus-related Liver Cirrhosis

<p>Patients' demography, clinical data, serum IgG-Fc glycan profiles, and cytokine profiles ar baseline and week 48 after treatment.</p>

opencc-zeroAug 2020View details →
zenodo32/100

Quantifying transmission dynamics of acute hepatitis C virus infections in a heterogeneous population using sequence data

<p>This upload contains data and all the scripts required to reproduce the results of the artice entitled &quot;Quantifying transmission dynamics of acute hepatitis C virus infections in a heterogeneous population using sequence data&quot;.</p> <p><strong>Code is located within Code.zip</strong> . It contains scripts in R and Bash and launchers. Some of the scripts require data files contained within Data.zip.</p> <p><strong>Data is located within Data.zip</strong> , such as the sequences, the inferred phylogeny and the Beast XML file.</p>

opencc-by-4.0Dec 2020View details →
dryad32/100

Effect of vitamin D supplementation in patients with chronic hepatitis C after direct-acting antiviral treatment: a randomized, double-blind, placebo-controlled trial

<p><b>Background: </b>Replacement of vitamin D (VD) among patients with chronic hepatitis C (CHC) before viral eradication has demonstrated a protective effect on serum markers associated with hepatic fibrogenesis. We therefore hypothesized that VD may facilitate further fibrosis amelioration following curative treatment with direct-acting antivirals (DAA). </p> <p><b>Methods: </b>This study was a randomized, double-blind, placebo-controlled trial conducted between February 2018 and August 2018. Patients with CHC and VD deficiency were randomized in a 1:1 ratio to either receive ergicalciferol or placebo over 6 weeks. Biochemical analysis indicators, including 25-hydroxyvitamin D (25(OH)D), fibrogenic markers [(transforming growth factor beta 1 (TGF-β1) and tissue inhibitors of matrix metalloproteinases 1 (TIMP-1)], and fibrolytic markers [matrix metalloproteinase 9 (MMP-9) and amino terminal type III procollagen peptide (P3NP)], were assessed at baseline and at 6 weeks. Serum 25(OH)D was analyzed by a chemiluminescence immunoassay. Serum hepatic fibrogenesis markers were measured using a quantitative sandwich enzyme-linked immunosorbent assay.</p> <p><b>Results: </b>Seventy-five patients with CHC and VD deficiency were randomly assigned to VD (n=37) and placebo (n=38) groups. At the end of the study, the mean serum 25(OH)D level had risen to a normal level in the VD group, but was still deficient in the placebo group (41.8±9.1 vs. 18.1±4.6 ng/mL, p&lt;0.001). Upon restoration of the VD level, there were no significant mean differences in the change from baseline for TGF-β1 (-0.6 ng/mL (95% confidence interval (95%CI) -2.8 – 1.7), p=0.63), TIMP-1 (-5.5 ng/mL (95%CI -26.4 – 15.3), p=0.60), MMP-9 (122.9 ng/mL (95%CI -69.0 – 314.8), p=0.21), and P3NP (-0.1 ng/mL (95%CI -2.4 – 2.2), p=0.92) between the VD and placebo groups. </p> <p><b>Conclusion: </b>Short-term VD supplementation after DAA treatment in patients with CHC does not improve serum fibrogenesis markers and may not expedite the residual liver fibrosis healing process. Future studies are warranted to evaluate the long-term effect of VD supplementation on hepatic fibrosis regression.</p>

opencc-zeroDec 2020View details →
dryad32/100

Data from: Hepatitis B virus sero-profiles and genotypes in HIV-1 infected and uninfected injection and non-injection drug users from coastal Kenya

Background: Information about HBV sero-markers, infection stages and genotypes in HIV-1 infected and uninfected injection and non-injection drug users (IDUs) in Kenya remains elusive. Methods: A cross-sectional study examining HBV sero-marker, infection stages and genotypes was conducted among HIV-1 infected and uninfected, respectively, IDUs (n = 157 and n = 214) and non-IDUs (n = 139 and n = 48), and HIV-1 uninfected non-drug using controls (n = 194) from coastal, Kenya. HBV sero-marker and infection stages were based on HBV 5-panel rapid test plasma sero-reactivity. DNA was extracted from acute and chronic plasma samples and genotypes established by nested-PCR and direct sequencing. Results: HBsAg positivity was higher in HIV-1 infected IDUs (9.6 %) relative to HIV-1 uninfected IDUs (2.3 %), HIV-1 infected non-IDUs (3.6 %), HIV-1 uninfected non-IDUs (0.0 %) and non-drug users (2.6 %; P = 0.002). Contrastingly, HBsAb positivity was higher in HIV-1 uninfected IDUs (14.6 %) and non-IDUs (16.8) in comparison to HIV-1 infected IDUs (8.3 %), and non-IDUs (8.6 %), and non-drug users (8.2 %; P = 0.023). HBcAb positivity was higher in HIV-1 infected IDUs (10.2 %) compared to HIV-1 uninfected IDUs (3.3 %), HIV-1 infected non-IDUs (6.5 %), HIV-1 uninfected non-IDUs (2.1 %) and non-drug users (4.6 %; P = 0.038). Acute (5.7 %, 1.4 %, 0.0 %, 0.0 % and 1.5 %) and chronic (5.1 %, 0.9 %, 3.6 %, 0.0 % and 1.5 %) stages were higher in HIV-1 infected IDUs, compared to HIV-1 uninfected IDUs, HIV-1 infected and uninfected non-IDUs and non-drug users, respectively. However, vaccine type response stage was higher in HIV-1 uninfected IDUs (15.4 %) relative to HIV-1 infected IDUs (6.4 %), and HIV-1 infected (6.5 %), and uninfected (10.4 %) non-IDUs, and non-drug users (5.7 %; P = 0.003). Higher resolved infection rates were also recorded in HIV-1 uninfected IDUs (11.2 %) compared to HIV-1 infected IDUs (8.3 %), and HIV-1 infected (7.2 %), uninfected (6.3 %) non-IDUs, and non-drug users (6.7 %; P = 0.479), respectively. Only A1 genotype showing minimal diversity was detected among the study participants. Conclusion: HBV sero-markers and infection staging are valuable in diagnosis and genotyping of HBV infections. Among IDUs, higher HBsAg and HBcAb positivity in HIV-1 infected and higher HBsAb positivity in HIV-1 negative IDUs suggests frequent exposure. Additionally, HBV genotype A is the dominant circulating genotype in both high and low risk populations of Kenya.

opencc-zeroDec 2014View details →
dryad32/100

Clinical significance of post-liver transplant hepatitis E seropositivity in high prevalence area of hepatitis E genotype 3: a prospective study

<p class="CxSpFirst">High hepatitis E (HEV) seroprevalence has been reported in the general population and in post-liver transplant (LT) cases in several regions, including Thailand, with genotype 3 being a predominant genotype. We hypothesized that HEV might persist at a subclinical level and might pose clinical risks in the post-LT period. We performed a cross-sectional study with 108 post-LT patients and found an IgG seroprevalence of 55.6%. Subsequently, 91 cases without clinical evidence of HEV-related hepatitis were enrolled in 1 year of prospective follow-up to determine clinical status, serologies and serum/feces HEV RNA every 4 months. HEV RNA was detected, indicating subclinical infections in patients with or without seropositivity, with an annual incidence of 7.7%. Our results suggest that subclinical HEV infection exists among LT patients in this high-prevalence area. Thus, clinicians should be aware of the possibility of disease reemergence and HEV viral transmission in LT patients.</p>

opencc-zeroMar 2020View details →
dryad32/100

Data from: Long-term benefit of hepatitis C therapy in a safety net hospital system: a cross-sectional study with median 5-year follow-up

Objectives: To demonstrate the effectiveness of hepatitis C virus (HCV) therapy and survival benefit from sustained virologic remission (SVR) in a safety net hospital population with limited resources. Design and setting: We conducted a retrospective cross-sectional study at an urban safety-net hospital in the U.S. Participants and intervention: 242 patients receiving standard HCV therapy between 2001 and 2006. Primary and secondary outcome measures: Response rates, including sustained virologic response (SVR), were recorded for each patient. Univariate and multivariate analyses were performed to identify predictors of SVR and 5 year survival. Results: A total of 242 eligible patients were treated. Treatment was completed in 197 (81%) patients, with 43 patients discontinuing therapy early – 32 due to adverse events and 11 due to non-compliance. Complications on treatment were frequent, including 3 deaths. SVR was achieved in 83 patients (34%). On multivariate analysis, independent predictors of a decreased likelihood of achieving SVR included African American race (OR 0.20, 95% CI 0.07 – 0.54), genotype 1 HCV infection (OR 0.25, 95% CI 0.13 – 0.50) and the presence of cirrhosis (OR 0.26, 95% CI 0.12 – 0.58). Survival was 98% in those achieving SVR (median follow-up 72 months) and 71% in non-responders and those discontinuing therapy (n = 91, median known follow-up 65 and 36 months respectively). On multivariate analysis, the only independent predictor of improved survival was SVR (HR 0.12, 95% CI 0.03 – 0.52). Both cirrhosis and hypoalbuminemia were independent predictors of increased mortality. Conclusions: HCV therapy can be effective despite limited resources. Survival is improved in those achieving SVR. Treatment before histologic cirrhosis develops, in combination with careful selection, may improve long-term outcomes without compromising other health care endeavors in safety net hospitals and areas with financial limitations.

opencc-zeroDec 2012View details →
dryad32/100

Data from: The burden of Hepatitis C virus infection in Punjab, India: a population-based serosurvey

Introduction: Hepatitis C virus (HCV) infection prevalence is believed to be elevated in Punjab, India; however, state-wide prevalence data are not available. An understanding of HCV prevalence, risk factors and genotype distribution can be used to plan control measures in Punjab. Methods: A cross-sectional, state-wide, population-based serosurvey using a multi-stage stratified cluster sampling design was conducted October 2013 to April 2014. Children aged &gt;5 years and adults were eligible to participate. Demographic and risk behavior data were collected, and serologic specimens were obtained and tested for anti-HCV antibody, HCV Ribonucleic acid (RNA) on anti-HCV positive samples, and HCV genotype. Prevalence estimates and adjusted odds ratios for risk factors were calculated from weighted data and stratified by urban/rural residence. Results: 5,543 individuals participated in the study with an overall weighted anti-HCV prevalence of 3.6% (95% Confidence Interval [CI]: 3.0%-4.2%) and chronic infection (HCV Ribonucleic acid test positive) of 2.6% (95% CI: 2.0%-3.1%). Anti-HCV was associated with being male (adjusted odds ratio 1.52; 95% CI: 1.08-2.14), living in a rural area (adjusted odds ratio 2.53; 95% CI: 1.62-3.95) and was most strongly associated with those aged 40-49 (adjusted odds ratio 40-49 vs 19-29-year-olds 3.41; 95% CI: 1.90-6.11). Anti-HCV prevalence increased with each blood transfusion received (adjusted odds ratio 1.36; 95% CI: 1.10-1.68) and decreased with increasing education, (adjusted odds ratio 0.37 for graduate-level vs. primary school/no education; 95% CI: 0.16-0.82). Genotype 3 (58%) was most common among infected individuals. Discussion: The study findings, including the overall prevalence of chronic HCV infection, associated risk factors and demographic characteristics, and genotype distribution can guide prevention and control efforts, including treatment provision. In addition to high-risk populations, efforts targeting rural areas and adults aged &gt;40 would be the most effective for identifying infected individuals.

opencc-zeroDec 2017View details →
dryad32/100

Data from: Untargeted metabolomic profiling of urine from healthy dogs and dogs with chronic hepatic disease

Chronic hepatic disease can present a diagnostic challenge with different etiologies being associated with similar clinical and laboratory findings. The histopathological assessment of a liver biopsy specimen is usually required in order to make a definitive diagnosis and the availability of non-invasive prognostic biomarkers is limited. The emerging science of metabolomics is used to detect changes in endogenous low molecular weight metabolites in biological samples and offers the possibility of identifying noninvasive markers of disease. The objective of this study was to investigate differences in the urine metabolome between healthy dogs, dogs with chronic hepatitis, dogs with hepatocellular carcinoma, and dogs with a congenital portosystemic shunt. Stored urine samples from 10 healthy dogs, 10 dogs with chronic hepatitis, 6 dogs with hepatocellular carcinoma, and 5 dogs with a congenital portosystemic shunt were analyzed. The urine metabolome was analyzed by gas chromatography – quadrupole time of flight mass spectrometry and 220 known metabolites were identified. Principal component analysis and heat dendrogram plots of the metabolomics data showed clustering between groups. Random forest analysis showed differences in the abundance of various metabolites including putrescine, gluconic acid, sorbitol, and valine. Based on univariate statistics, 37 metabolites were significantly different between groups. In, conclusion, the urine metabolome varies between healthy dogs, dogs with chronic hepatitis, dogs with hepatocellular carcinoma, and dogs with a congenital portosystemic shunt. Further targeted assessment of these metabolites is needed to assess their diagnostic utility.

opencc-zeroJun 2019View details →
zenodo32/100

Dataset for "Joint zonated quantification of multiple parameters in hepatic lobules"

<p>Datasets for the publication "Joint zonated quantification of multiple parameters in hepatic lobules", available at Research Square <a href="https://doi.org/10.21203/rs.3.rs-4764718/v1">https://doi.org/10.21203/rs.3.rs-4764718/v1</a></p>

opencc-by-4.0Jul 2024View details →
dryad32/100

Gut microbiota-derived gamma-aminobutyric acid from metformin treatment reduces hepatic ischemia/reperfusion injury by inhibiting ferroptosis

<div>Hepatic ischemia/reperfusion injury (HIRI) is a common and inevitable factor leading to poor prognosis in various liver diseases, making the outcomes of current treatments in the clinic unsatisfactory. Metformin has been demonstrated to be beneficial in alleviating HIRI in recent studies, however, the underpinning mechanism remains unclear. In this study, we found metformin mitigates HIRI-induced ferroptosis through reshaped gut microbiota in mice, which was confirmed by the results of fecal microbiota transplantation treatment but showed the elimination of the beneficial effects when gut bacteria were depleted using antibiotics. Detailedly, through 16S rRNA and metagenomic sequencing, we identified that the metformin-reshaped microbiota was characterized by the increase of gamma-aminobutyric acid (GABA) producing bacteria. This increase was further confirmed by the elevation of GABA synthesis key enzymes, glutamic acid decarboxylase, and putrescine aminotransferase, in gut microbes of metformin-treated mice and healthy volunteers. Furthermore, the benefit of GABA against HIRI-induced ferroptosis was demonstrated in GABA-treated mice. Collectively, our data indicate that metformin can mitigate HIRI-induced ferroptosis by reshaping gut microbiota, with GABA identified as a key metabolite.</div>

opencc-zeroMar 2024View details →
zenodo32/100

CD127 as a Novel Potential Marker for Clearance in Chronic Hepatitis C Virus Patients

Open the record for dataset details and reuse information.

opencc-by-4.0Aug 2015View details →
zenodo32/100

Left hepatectomy with concomitant the right hepatic artery and the portal vein resection

<p>The supplemental video shows our procedure for HAR in PHCC (supplemental video). The first step of the surgical procedure for HAR was similar to the standard resection for PHCC surgery: lymphadenectomy (skeletonization) for the hepatoduodenal ligament and distal bile duct resection just above the posterior superior pancreatic duodenal artery. We usually pick up the right hepatic artery (or posterior branch) at Rouviere&rsquo;s sulcus before skeletonization around the proper hepatic artery to confirm resectability. Hepatic artery reconstruction is usually performed as the final step after bile duct and portal vein resection and reconstruction.</p>

opencc-by-4.0Mar 2022View details →
dryad32/100

The timing of spring warming shapes reproductive effort in a warm-water fish: the role of mismatches between hepatic and gonadal processes

Spring-spawning fishes native to northern environments rely on both increasing temperature and lengthening photoperiod to cue reproduction and may thus be particularly sensitive to rapid warming earlier in the year while day lengths remain short. We investigated the reproductive response of pumpkinseed sunfish Lepomis gibbosus to spring warming commencing at a range of day lengths (9 – 15 hours), corresponding to various calendar days (January 10 – May 22). In both the laboratory and field, both male and female fish that experienced early warming while day lengths were &lt;11 hours: 1) failed to initiate reproductive preparation in the liver before gonad development began, and 2) had reduced reproductive allocation. Analysis of published data on temperate fishes suggested that liver development prior to gonad development is widespread across warm-, cool-, and cold-water thermal guilds, though the precise phenology of liver relative to gonad development appears to vary widely among species. Together, our results point toward dampened reproductive preparation as a novel mechanism mediating reduced reproductive output in both warm- and cool-water fish following earlier spring warming.

opencc-zeroMar 2022View details →

ScienceDex guides

Understand access before you commit

These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.

Compare curated datasets

Allen Brain Atlas

Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.

allen-brain-atlas
neuroscienceopenDocumentation, web resources, and API references are available online.
Last verified 2026-04-30Open record

Annotated Behaviour and Observability Dataset (ABODe)

ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.

abode-home-cage
behavioral-neuroscienceopenThe DataShare record exposes download links for annotations, documentation, license text, and the zipped per-snippet data directory.
Last verified 2026-04-30Open record

DANDI Archive for NWB datasets

DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.

dandi-nwb
electrophysiologyopenPublished Dandiset metadata and archive endpoints are available through the production DANDI API.
Last verified 2026-04-30Open record

International Brain Laboratory public data

The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.

ibl
behavioral-neuroscienceopenPublic sessions can be searched and loaded from the IBL public data server through ONE.
Last verified 2026-04-29Open record

OpenNeuro

OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.

openneuro
neuroscienceopenPublished datasets are available on demand over the internet.
Last verified 2026-04-29Open record

ScienceDex for faculty

Your academic CV and NIH biosketch

Make your CV in your school's format and your NIH biosketch from it, then download both as Word files.